Jason Eric Evans Sells 11,462 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CEO Jason Eric Evans sold 11,462 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.79, for a total value of $158,060.98. Following the completion of the sale, the chief executive officer directly owned 662,680 shares of the company’s stock, valued at approximately $9,138,357.20. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Surgery Partners Stock Down 2.6%

SGRY stock opened at $12.95 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $1.68 billion, a PE ratio of -20.89 and a beta of 1.95. Surgery Partners, Inc. has a 1-year low of $12.25 and a 1-year high of $24.60. The business’s 50 day simple moving average is $15.10 and its 200 day simple moving average is $17.93.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business had revenue of $885.00 million for the quarter, compared to analyst estimates of $866.54 million. During the same period in the prior year, the business earned $0.44 EPS. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, research analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Surgery Partners declared that its board has approved a stock buyback plan on Thursday, February 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 9.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors have recently modified their holdings of the business. Pentwater Capital Management LP grew its stake in shares of Surgery Partners by 66.9% in the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after acquiring an additional 4,681,000 shares in the last quarter. UBS Group AG raised its stake in Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after purchasing an additional 4,113,052 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Surgery Partners by 528.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after purchasing an additional 1,647,714 shares in the last quarter. Glenview Capital Management LLC bought a new stake in Surgery Partners in the 2nd quarter valued at about $33,995,000. Finally, King Street Capital Management L.P. boosted its holdings in Surgery Partners by 24.5% in the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock valued at $138,382,000 after purchasing an additional 1,225,000 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on SGRY shares. Royal Bank Of Canada reduced their target price on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, March 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Surgery Partners in a report on Wednesday, March 4th. UBS Group cut their price objective on shares of Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. JPMorgan Chase & Co. reduced their price objective on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.60.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus remains constructive — several brokerages rate SGRY as a “Moderate Buy,” which supports baseline investor demand. Brokerage Recommendation
• Positive Sentiment: Investor conference access: Management presented at the Barclays 28th Annual Global Healthcare Conference (Mar 10), providing a forum to reiterate guidance and margin improvement plans — useful upside catalyst if commentary is clear and credible. Prepared Remarks Transcript
• Positive Sentiment: Short interest fell ~15.7% in February (still ~11% of float but lower than mid‑month), which reduces one source of bearish positioning and could limit further short-driven price pressure.
• Neutral Sentiment: Prepared remarks and Q4 write‑ups: Recent transcripts and industry Q4 summaries provide more detail on volumes and outpatient trends but contain no single new, market‑moving disclosure. Q4 Coverage
• Negative Sentiment: Activist pressure: Ortelius Capital is pushing for board changes and asset sales, increasing the chance of near‑term strategic disruption, management turnover or contentious proxy fights. Activist Story
• Negative Sentiment: Fraud probe announced: Law firm Levi & Korsinsky opened an investigation into prior management statements on margin expansion, raising potential legal/settlement risk and heightening investor uncertainty. Fraud Investigation
• Negative Sentiment: Significant insider selling: Multiple executives (CEO, CFO and other officers) sold sizable blocks the week of Mar 5–6 at roughly $13.60–$13.93, which the market often interprets negatively for near‑term confidence. Representative SEC filing: CEO Sale Filing
• Negative Sentiment: Recent earnings execution: The March 2 Q4 report showed a meaningful EPS miss (revenue slight beat but EPS well below street), highlighting execution/margin risk that underpins some of the legal and activist scrutiny.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.